✉ info@591daili.com☎ +86-18553102138
📞 WhatsApp中文
Home › Product Catalog › Relugolix

Relugolix

CAS 737789-87-6C29H27F2N7O5SMW 623.6

Relugolix (CAS 737789-87-6) — formula C29H27F2N7O5S, molecular weight 623.6.

Product Overview

CAS Number737789-87-6
Molecular FormulaC29H27F2N7O5S
Molecular Weight623.6
LogP1.69

Technical Profile

What this product is

Relugolix is a chemical compound with CAS registry number 737789-87-6 and molecular formula C29H27F2N7O5S (molecular weight 623.6).

Identification

CAS number: 737789-87-6

Its molecular formula C29H27F2N7O5S comprises 29 C, 27 H, 2 F, 7 N, 5 O, 1 S atoms.

Also known as: Relugolix · 雷鲁戈利克斯

Frequently Asked Questions

What is the CAS number of Relugolix?

The CAS registry number of Relugolix is 737789-87-6.

What is the molecular formula and molecular weight of Relugolix?

Molecular formula C29H27F2N7O5S, molecular weight 623.6.

What other names is Relugolix known by?

It is also registered under: Relugolix, 雷鲁戈利克斯.

PubChem Public Data

Independent reference data for Relugolix (CAS 737789-87-6), compiled from public chemistry databases.

Registry identifiers across databases

CAS Registry Number737789-87-6
PubChem CID10348973
Molecular formulaC29H27F2N7O5S
IUPAC name1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
UNII (FDA)P76B05O5V6

Computed descriptors

Molecular Weight623.6
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count9
Exact Mass623.17624448
Monoisotopic Mass623.17624448
Topological Polar Surface Area157
Heavy Atom Count44

Physicochemical values on record

LogP1.69

Documented uses on record

    Relugolix is indicated for the treatment of adult patients with advanced prostate cancer. In a combination product with [estradiol] and [norethindrone], relugolix is indicated for the once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.Relugolix is an orally administered, small molecule antagonist of gonadotropin releasing hormone (GnRH) that effectively blocks androgen production and is used to treat advanced prostate cancer. Relugolix therapy may be associated with a low rate of serum enzyme elevations during therapy, but has yet to be linked to instances of clinically apparent acute liver injury.

    Synonyms and trade names

    Relugolix; 737789-87-6; TAK-385; Orgovyx; TAK 385; TAK385; P76B05O5V6; DTXSID40224167; MYFEMBREE COMPONENT RELUGOLIX; relugolixum; RefChem:57784; DTXCID40146658; MFCD25976856; C29H27F2N7O5S; CHEMBL1800159; Relugolix [USAN:INN]

    GHS hazard classification

    Reported hazard statementsH360 (20%), H361 (60%), H371 (40%), H373 (20%), H411 (20%)

    H360 (20%): May damage fertility or the unborn child [Danger Reproductive toxicity]

    H361 (60%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

    What the public record says

    Relugolix · CAS 737789-87-6 · C29H27F2N7O5S. UNII P76B05O5V6. LogP: 1.69.

    Source: PubChem / Wikidata; the batch COA governs where values differ.

Request a Quote

✉ info@591daili.com☎ +86-18553102138📞 WhatsAppEmail InquiryWhatsApp Inquiry

Supplier: Jinan Shenghe Chemical Co., Ltd.

中文页面: 雷鲁戈利克斯

鲁ICP备19031700号-2